Pablo S Contreras1, Marcelo Gonzalez-Zuñiga2, Lila González-Hódar3, María José Yáñez1, Andrés Dulcey4, Juan Marugan4, Edward Seto5, Alejandra R Alvarez6, Silvana Zanlungo7. 1. Department of Cell and Molecular Biology, Pontificia Universidad Católica de Chile, Santiago, Chile; CARE UC Pontificia Universidad Católica de Chile, Santiago, Chile; Departamento de Gastroenterología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. 2. Department of Cell and Molecular Biology, Pontificia Universidad Católica de Chile, Santiago, Chile. 3. Departamento de Gastroenterología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. 4. National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA. 5. Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. 6. Department of Cell and Molecular Biology, Pontificia Universidad Católica de Chile, Santiago, Chile; CARE UC Pontificia Universidad Católica de Chile, Santiago, Chile. Electronic address: aalvarez@bio.puc.cl. 7. Departamento de Gastroenterología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile; FONDAP Center for Genome Regulation (CGR), Santiago, Chile. Electronic address: silvana@med.puc.cl.
Abstract
BACKGROUND: Niemann-Pick type C (NPC) disease is a fatal neurodegenerative disorder characterized by the accumulation of free cholesterol in lysosomes. There are currently no effective FDA-approved treatments for NPC, although in the last years the inhibition of histone deacetylases (HDACs) has emerged as a potential treatment for this disease. However, the molecular mechanisms that deregulate HDAC activity in NPC disease are unknown. Previously our group had shown that the proapoptotic tyrosine kinase c-Abl signaling is activated in NPC neurons. Here, we demonstrate that c-Abl activity increases HDAC2 levels inducing neuronal gene repression of key synaptic genes in NPC models. RESULTS: Our data show that: i) HDAC2 levels and activity are increased in NPC neuronal models and in Npc1(-/-) mice; ii) inhibition of c-Abl or c-Abl deficiency prevents the increase of HDAC2 protein levels and activity in NPC neuronal models; iii) c-Abl inhibition decreases the levels of HDAC2 tyrosine phosphorylation; iv) treatment with methyl-β-cyclodextrin and vitamin E decreases the activation of the c-Abl/HDAC2 pathway in NPC neurons; v) in vivo treatment with two c-Abl inhibitors prevents the increase of HDAC2 protein levels in the brain of Npc1(-/-) mice; and vi) c-Abl inhibition prevents HDAC2 recruitment to the promoter of neuronal genes, triggering an increase in their expression. CONCLUSION: Our data show the involvement of the c-Abl/HDAC2 signaling pathway in the regulation of neuronal gene expression in NPC neuronal models. Thus, inhibition of c-Abl could be a pharmacological target for preventing the deleterious effects of increased HDAC2 levels in NPC disease.
BACKGROUND:Niemann-Pick type C (NPC) disease is a fatal neurodegenerative disorder characterized by the accumulation of free cholesterol in lysosomes. There are currently no effective FDA-approved treatments for NPC, although in the last years the inhibition of histone deacetylases (HDACs) has emerged as a potential treatment for this disease. However, the molecular mechanisms that deregulate HDAC activity in NPC disease are unknown. Previously our group had shown that the proapoptotic tyrosine kinase c-Abl signaling is activated in NPC neurons. Here, we demonstrate that c-Abl activity increases HDAC2 levels inducing neuronal gene repression of key synaptic genes in NPC models. RESULTS: Our data show that: i) HDAC2 levels and activity are increased in NPC neuronal models and in Npc1(-/-) mice; ii) inhibition of c-Abl or c-Abl deficiency prevents the increase of HDAC2 protein levels and activity in NPC neuronal models; iii) c-Abl inhibition decreases the levels of HDAC2tyrosine phosphorylation; iv) treatment with methyl-β-cyclodextrin and vitamin E decreases the activation of the c-Abl/HDAC2 pathway in NPC neurons; v) in vivo treatment with two c-Abl inhibitors prevents the increase of HDAC2 protein levels in the brain of Npc1(-/-) mice; and vi) c-Abl inhibition prevents HDAC2 recruitment to the promoter of neuronal genes, triggering an increase in their expression. CONCLUSION: Our data show the involvement of the c-Abl/HDAC2 signaling pathway in the regulation of neuronal gene expression in NPC neuronal models. Thus, inhibition of c-Abl could be a pharmacological target for preventing the deleterious effects of increased HDAC2 levels in NPC disease.
Authors: Mark Kilgore; Courtney A Miller; Daniel M Fass; Krista M Hennig; Stephen J Haggarty; J David Sweatt; Gavin Rumbaugh Journal: Neuropsychopharmacology Date: 2009-12-09 Impact factor: 7.853
Authors: Alejandra R Alvarez; Pablo C Sandoval; Nancy R Leal; Paula U Castro; Kenneth S Kosik Journal: Neurobiol Dis Date: 2004-11 Impact factor: 5.996
Authors: Ji-Song Guan; Stephen J Haggarty; Emanuela Giacometti; Jan-Hermen Dannenberg; Nadine Joseph; Jun Gao; Thomas J F Nieland; Ying Zhou; Xinyu Wang; Ralph Mazitschek; James E Bradner; Ronald A DePinho; Rudolf Jaenisch; Li-Huei Tsai Journal: Nature Date: 2009-05-07 Impact factor: 49.962
Authors: Maria João Nunes; Miguel Moutinho; Maria João Gama; Cecília M P Rodrigues; Elsa Rodrigues Journal: PLoS One Date: 2013-01-10 Impact factor: 3.240
Authors: Tamara Marín; Andrés E Dulcey; Fabián Campos; Catalina de la Fuente; Mariana Acuña; Juan Castro; Claudio Pinto; María José Yañez; Cristian Cortez; David W McGrath; Pablo J Sáez; Kirill Gorshkov; Wei Zheng; Noel Southall; Maria Carmo-Fonseca; Juan Marugán; Alejandra R Alvarez; Silvana Zanlungo Journal: Front Cell Dev Biol Date: 2022-03-18
Authors: Daniela A Gutiérrez; América Chandía-Cristi; María José Yáñez; Silvana Zanlungo; Alejandra R Álvarez Journal: Neural Regen Res Date: 2023-02 Impact factor: 6.058
Authors: Tino W Sanchez; Michael H Ronzetti; Ashley E Owens; Maria Antony; Ty Voss; Eric Wallgren; Daniel Talley; Krishna Balakrishnan; Sebastian E Leyes Porello; Ganesha Rai; Juan J Marugan; Samuel G Michael; Bolormaa Baljinnyam; Noel Southall; Anton Simeonov; Mark J Henderson Journal: ACS Chem Biol Date: 2022-09-01 Impact factor: 4.634
Authors: Sandra Torres; Elisa Balboa; Silvana Zanlungo; Carlos Enrich; Carmen Garcia-Ruiz; Jose C Fernandez-Checa Journal: Front Physiol Date: 2017-11-30 Impact factor: 4.566